BRAF and central nervous system cancer: Encouraging preliminary results from this study have reported complete responses in the two glioblastoma cases enroled in the trial.292 Dabrafenib/trametinib is currently in clinical trials for newly diagnosed and recurrent glioma patients with the BRAF V600E mutation (NCT03919071, NCT03593993).